Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs.
- 1 November 1993
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 88 (5), 2337-2350
- https://doi.org/10.1161/01.cir.88.5.2337
Abstract
BACKGROUND It has recently been demonstrated that myocardial ischemia and reperfusion results in a marked decrease in the release of nitric oxide (NO) by the coronary endothelium. NO may possess cardioprotective properties, possibly related to inhibition of neutrophil-related activities. We tested the hypothesis that a cysteine-containing nitric oxide donor compound, SPM-5185, would reduce infarct size and inhibit neutrophil-related activities (adherence to coronary vascular endothelium, accumulation). METHODS AND RESULTS The effects of intracoronary infusion of SPM-5185 were investigated in a 5.5-hour model of myocardial ischemia (1 hour) and reperfusion (4.5 hours) (MI-R) in anesthetized, open-chest dogs. SPM-5185 (500 nmol/L) or saline vehicle was infused for 4.5 hours into the left anterior descending coronary artery (LAD) at the time of reperfusion after 1 hour of LAD occlusion. MI-R in dogs receiving saline vehicle resulted in severe myocardial injury characterized by dyskinesis, a profound elevation of plasma creatine kinase, marked myocardial necrosis, and high cardiac myeloperoxidase (MPO) activity in the ischemic and necrotic zones. In contrast, treatment with SPM-5185 resulted in a modest restoration of regional function, a reduction of myocardial necrosis expressed as a percentage of the area at risk (12.5 +/- 3.2% versus 41.7 +/- 5.4%, P < .001), and significant reductions of MPO activity in the ischemic zone (0.8 +/- 0.1 versus 2.5 +/- 0.7 U/100 mg tissue, P < .05) and the necrotic zone (1.6 +/- 0.2 versus 3.3 +/- 0.6 U/100 mg tissue, P < .05). In additional studies, SPM-5185 (500 nmol/L) significantly (P < .001) attenuated the adherence of LTB4-stimulated canine neutrophils to autologous segments of coronary artery and attenuated the neutrophil-induced contraction of isolated coronary arterial rings. CONCLUSIONS SPM-5185 reduces myocardial necrosis and neutrophil accumulation in an acute model of canine myocardial ischemia and reperfusion. This reduction in myocardial cell injury may be partially related to the inhibitory actions of this novel NO donor on neutrophil adherence to the coronary endothelium.Keywords
This publication has 27 references indexed in Scilit:
- Controlled coronary hydrodynamics at the time of reperfusion reduces postischemic injuryCoronary Artery Disease, 1992
- Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion.Journal of Clinical Investigation, 1991
- Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusionCritical Care Medicine, 1991
- A method for isolation and fluorescent labeling of rat neutrophils for intravital microvascular studiesMicrovascular Research, 1990
- Sodium nitroprusside and positive end-expiratory pressure are not detrimental in canine asymmetric pulmonary edemaCritical Care Medicine, 1989
- Neutrophils as potential participants in acute myocardial ischemia: Relevance to reperfusionJournal of the American College of Cardiology, 1988
- Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion.Journal of Clinical Investigation, 1988
- Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro.Journal of Clinical Investigation, 1987
- Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemie myocardiumJournal of Pharmacological Methods, 1985
- Myeloperoxidase Activity as a Quantitative Marker of Polymorphonuclear Leukocyte Accumulation into an Experimental Myocardial Infarct—The Effect of Ibuprofen on Infarct Size and Polymorphonuclear Leukocyte AccumulationJournal of Cardiovascular Pharmacology, 1985